CD274 and non-small cell lung carcinoma: Different monoclonal antibodies targeting the programmed death 1 (PD-1) or PD-1 ligand (PD-L1) are currently used for the treatment of metastatic melanoma, non-small cell lung cancer (NSCLC), classic Hodgkin’s lymphoma, urothelial bladder, renal cell and head and neck squamous cell carcinomas [1,2,3,4,5,6,7,8,9,10].